Role of α1‐blockers in the current management of hypertension-Reference-Cited by-同舟云学术

Role of α1‐blockers in the current management of hypertension

Published:2022-09 Issue:9 Volume:24 Page:1180-1186
ISSN:1524-6175
Container-title:The Journal of Clinical Hypertension
language:en
Short-container-title:J of Clinical Hypertension

Author:

Li Hua¹,Xu Ting‐Yan¹,Li Yan¹^ORCID,Chia Yook‐Chin²³^ORCID,Buranakitjaroen Peera⁴,Cheng Hao‐Min⁵⁶⁷⁸^ORCID,Van Huynh Minh⁹^ORCID,Sogunuru Guru Prasad¹⁰¹¹^ORCID,Tay Jam Chin¹²^ORCID,Wang Tzung‐Dau¹³¹⁴^ORCID,Kario Kazuomi¹⁵^ORCID,Wang Ji‐Guang¹^ORCID

Affiliation:

1. The Shanghai Institute of Hypertension Ruijin Hospital Shanghai Jiao Tong University School of Medicine Shanghai China

2. Department of Medical Sciences, School of Medical and Life Sciences Sunway University Bandar Sunway Malaysia

3. Department of Primary Care Medicine, Faculty of Medicine University of Malaya Kuala Lumpur Malaysia

4. Division of Hypertension, Department of Medicine Faculty of Medicine Siriraj Hospital Mahidol University Bangkok Thailand

5. Center for Evidence‐based Medicine Taipei Veterans General Hospital Taipei Taiwan

6. Ph.D. Program of Interdisciplinary Medicine (PIM) National Yang Ming Chiao Tung University College of Medicine Taipei Taiwan

7. Institute of Public Health National Yang Ming Chiao Tung University College of Medicine Taipei Taiwan

8. Institute of Health and Welfare Policy National Yang Ming Chiao Tung University College of Medicine Taipei Taiwan

9. Department of Internal Medicine Hue University of Medicine and Pharmacy, Hue University Hue Vietnam

10. MIOT International Hospital Chennai Tamil Nadu India

11. College of Medical Sciences Kathmandu University Bharatpur Nepal

12. Department of General Medicine Tan Tock Seng Hospital Singapore Singapore

13. Cardiovascular Center and Division of Cardiology, Department of Internal Medicine National Taiwan University Hospital Taipei City Taiwan

14. Division of Hospital Medicine, Department of Internal Medicine National Taiwan University Hospital Taipei City Taiwan

15. Division of Cardiovascular Medicine, Department of Medicine Jichi Medical University School of Medicine Tochigi Japan

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jch.14556

Reference57 articles.

1. Prazosin Hydrochloride (CP‐12,299‐1), An Oral Anti‐Hypertensive Agent: Preliminary Clinical Observations in Ambulatory Patients

2. A pharmacodynamic and pharmacokinetic assessment of a new alpha- adrenoceptor antagonist, doxazosin (UK33274) in normotensive subjects.

3. Antihypertensive effectiveness of terazosin: A new long-acting alpha-adrenergic inhibitor

4. 1999 World Health Organization‐International Society of Hypertension guidelines for the management of hypertension;Guidelines Subcommittee;J Hypertens,1999

5. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension;European Heart Journal;2024-08-30

2. Bioequivalence Analysis of Terazosin Hydrochloride Tablets Based on Parallel Artificial Membrane Permeability Analysis;Pharmaceuticals;2024-08-05

3. Discovery of MT-1207: A Novel, Potent Multitarget Inhibitor as a Promising Clinical Candidate for the Treatment of Hypertension;Journal of Medicinal Chemistry;2024-07-05

4. Serum Levels of Prostate Specific Antigen and Specific Reproductive Hormones Among Male Subjects with Benign Prostate Hyperplasia in Port Harcourt, Nigeria;Annals of Innovation in Medicine;2024-04-25

5. Terazosin attenuates abdominal aortic aneurysm formation by downregulating Peg3 expression to inhibit vascular smooth muscle cell apoptosis and senescence;European Journal of Pharmacology;2024-04